AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

February 5, 2026

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence

LATHAM, N.Y.--(BUSINESS WIRE)--Feb. 5, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent PE research.

Pulmonary embolism affects approximately one in 1,000 people annually[1]. It is estimated to contribute to more than 50,000 deaths each year in the United States,[2] underscoring the need for continued clinical research and innovation.

The ALPHA-PE Research Fund is designed to support independent, physician-led research addressing critical evidence gaps in pulmonary embolism care, where a lack of real-world data often limits clinical decision-making. By enabling investigator-driven studies, the program aims to accelerate the generation of clinically relevant evidence to inform care delivery and advance understanding of PE management.

Awards ranging from $50,000 to $750,000 over one to three years will be distributed, empowering both established and emerging investigators to pursue data-driven research focused on patient outcomes, workflow optimization, or novel therapeutic approaches with the potential to improve real-world PE care.

"This initiative reflects our commitment to supporting the cardiovascular community in closing critical data gaps in pulmonary embolism care," said Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International at AngioDynamics. "By supporting investigator-led studies, we strengthen the evidence base for approaches that can improve patient outcomes and advance the standard of care."

"Independent, physician-led research plays a critical role in generating real-world insight in treating pulmonary embolism," said Juan Carlos Serna, Senior Vice President of Scientific & Clinical Affairs at AngioDynamics. "The ALPHA-PE Research Fund is designed to foster science-driven collaboration that advances understanding and care for patients."

Investigators interested in applying to the ALPHA-PE Research Fund are invited to submit a brief Letter of Intent outlining study objectives, design, and budget. Selected applicants will be invited to submit full proposals for review.

"We are incredibly excited about this collaboration and the opportunity it creates for the PE community," said Amir Darki, MD, Co-Chair of the National PERT Research Consortium®. "Physician-led, investigator-driven research is essential to closing critical evidence gaps in pulmonary embolism care. The ALPHA-PE Research Fund represents a meaningful investment in supporting innovation, fostering collaboration, and advancing impactful research that will directly inform real-world practice and improve patient outcomes."

For additional information about the ALPHA-PE Research Fund, including submission guidelines and timelines, visit angiodynamics.com/alpha-pe-research-fund/.

About the ALPHA-PE Research Fund

The ALPHA-PE Research Fund is a collaborative, investigator-led initiative launched by AngioDynamics in partnership with The PERT Consortium® to support independent research advancing the understanding and treatment of pulmonary embolism. The fund is designed to address critical evidence gaps by enabling physician-driven studies focused on real-world clinical practice, patient outcomes, and innovation in PE care. Through competitive grants awarded to both established and emerging investigators, the ALPHA-PE Research Fund aims to advance clinically relevant evidence and support continued progress in pulmonary embolism management.

About The PERT Consortium®

The purpose of The PERT Consortium® is to serve the general public by undertaking activities to advance the status of PE care and promote research in the treatment of pulmonary embolism. Specifically, the Consortium's purpose is to:

- Promote the adoption of the PERT model in healthcare institutions across the United States to ensure the prompt diagnosis and treatment of pulmonary embolism.
- Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors.
- Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.

By focusing solely on the entity of pulmonary embolism – its etiology, pathophysiology, prevention, management approach, outcomes of specific treatments, and follow-up pathways – it is the intention of the Consortium to increase awareness of treatment options available to patients with PE, to reduce its incidence worldwide, to improve health outcomes, and to positively influence the impact of this terrible disease. Visit, pertconsortium.org to learn about current initiatives, programs, and how to get involved.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,

expanding cancer treatment options and improving patient quality of life.

The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.

[1] https://www.lung.org/blog/pulmonary-embolism-risk-factors
[2] https://www.uptodate.com/contents/pulmonary-embolism-beyond-the-basics/print

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205480931/en/

Investor Contact:
Stephen Trowbridge
Executive Vice President & CFO
518-795-1408
strowbridge@angiodynamics.com

Media Contact:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com

Source: AngioDynamics, Inc.